Australian people can buy antibiotics in Australia online here: http://buyantibioticsaustralia.com/ No prescription required and cheap price!

Provost.wsu.edu

CURRICULUM VITAE
The University of Texas at AustinDivision of Pharmacology and ToxicologyCollege of PharmacyAustin, Texas 78712 www.utexas.edu/pharmacy/divisions/pharmtox/faculty/kehrer.html 10435 Jennys Jump DrAustin, Texas 78733-3216 Paul L. Kehrer, July 21, 1982Marc D. Kehrer, February 27, 1986 Education
Watertown Senior High School, Watertown, WI 53094
Purdue University, West Lafayette, IN 47907 Univ. of Iowa College of Medicine, Iowa City, IA 52242 Postdoctoral - Biology Division, Oak Ridge National Membership - Societies
American Association for the Advancement of Science (1975-present)
American Association for Cancer Research (1999-present)
American Society for Pharmacology and Experimental Therapeutics (1984-present). Chairman,
Society of Toxicology (1982-present); President of Mechanisms Specialty Section, 1998-99Society for Free Radical Biology and Medicine (1988-present; formerly the Oxygen Society)International Society for Free Radical Research (1986-present)Gulf Coast Chapter Society of Toxicology (1989-present) Vice-President 1989; President 1990International Society for the Study of Xenobiotics (ISSX) (1993-97)Western Pharmacology Society (1984-1998) Awards and Honors
1. Merck Award in Pharmacology (1974 - Purdue)
2. Rho Chi National Pharmacy Honorary
3. Phi Kappa Phi Honorary Society
4. University of Iowa Graduate College Fellowship in Pharmacology 1974-1975
5. Postdoctoral Investigatorship - University of Tennessee-Oak Ridge Graduate School of
Biomedical Sciences, Oak Ridge National Laboratory, Biology Division. 1978-1980.
6. University of Texas Summer Research Award - 1981
7. Research Career Development Award - National Institutes of Health (NHLBI) 1984-1989
8. Gustavus Pfeiffer Centennial Endowed Fellowship in Pharmacology - 1985-1991
9. Achievement Award - Society of Toxicology 1989.
10. Gustavus and Louise Pfeiffer Professorship in Toxicology - 1991-present.
11. Zeneca Traveling Lectureship Award, Society of Toxicology 1996.
12. Univ. of Texas College of Pharmacy Alumni Association “Best Friend” Award, Nov. 1, 200113. Distinguished Alumnus Award, Purdue Univ. School of Pharmacy, 2004 Curriculum Vitae
Kehrer, J.P.
Page 2

Experience
Director, Center for Molecular and Cellular Toxicology
Member, US-EPA Science Advisory Board Environmental Health Committee 2003-2006Adjunct Professor, Dept. Carcinogenesis, M.D. Anderson Cancer Center, Science Park Research DivisionHead, Division of Pharmacology and Toxicology, College of Pharmacy Professor of Pharmacology - University of Texas at Austin Guest Scientist - Universität Düsseldorf Visiting Professor - Institut Für Physiologische Chemie I, Universität Düsseldorf, Düsseldorf, West Germany (with Dr. Helmut Sies) Associate Professor of Pharmacology - University of Texas at Austin Assistant Professor of Pharmacology - University of Texas at Austin Postdoctoral Investigator-Biology Div., Oak Ridge National Laboratory (with Dr. Hanspeter Witschi) NIH Predoctoral Fellow, Univ. of Iowa (with Dr. Anne P. Autor) RESEARCH
Research Interests
•Molecular mechanisms by which acrolein, a cyclophosphamide metabolite, affects apoptosis and
cell proliferation; effects on NF-κB; role of acrolein in the anticancer efficacy of this drug
•Thioredoxin and apoptosis; role of thioredoxin in signaling•Mechanisms of apoptosis induced by lipoxygenase and cyclooxygenase-2 inhibitors; role oflipocalin expression (24p3 and NGAL) and Akt signaling pathways•Free radical toxicity; glutathione and apoptosis Research Support (direct costs)
A. Past Funding
1.
Univ. of Texas Research Institute. "Effect of Butylated Hydroxytoluene on PulmonaryGlutathione Levels". $4,800: October 1980-March 31, 1981, Principal Investigator.
Univ. of Texas Research Institute. "The Effect of Corticosteroids on Acutely DamagedPulmonary Tissue," $4,000, Summer Research Award, June 1, 1981-August 31, 1981.
College of Pharmacy BRSG Seed Grant. "Hydroxyproline as an Index of Collagen ContentAfter Acute Lung Damage", $5,000: June 15, 1981-March 31, 1982, Principal Investigator Univ. of Texas Research Institute. "The Effect of Acute Lung Damage on the Breakdown ofCollagen" $5,000: Sept. 30, 1981-July 31, 1982, Principal Investigator Gustavus and Louise Pfeiffer Research Foundation. "The Effect of Drug Treatment onDamaged Lung Tissue" $50,023: October 1982-September 1985, Principal Investigator.
College of Pharmacy BRSG Seed Grant. "The Effects of BCNU (carmustine) on PulmonaryGlutathione Reductase". $2,000: June 15, 1982-March 31, 1983, Principal Investigator.
Univ. of Texas Research Institute."The Effect of Drug Treatment on Damaged Lung Tissue".
$5,000: October 1982-March 1983, Principal Investigator.
National Institutes of Health (NHLBI). "Effect of Toxic Lung Damage and Steroids onCollagen" $167,612: April 1, 1983-March 31, 1986, Principal Investigator.
American Heart Assoc.-Texas Affiliate. "Enhanced Doxorubicin Cardiotoxicity by BCNU".
$28,771: July 1, 1983-June 30, 1984, Principal Investigator.
10. American Cancer Society."Toxic Effects of BCNU: Role of Glutathione Reductase Inhibition." $72,355: July 1, 1983 - June 30, 1985, Principal Investigator.
11. College of Pharmacy BRSG Seed Grant. "Role of Lipid Peroxide Damage in Chicken Muscular Dystrophy". $2,000: June 1, 1985 - March 31, 1986.
12. American Cancer Society. "Toxic Interactions of Anticancer Drugs on the Lung" $37,575: July 1, 1985 - June 30, 1986, Principal Investigator.
13. General Motors Research Institute. "Analysis of Lung Collagen in Ozone-Exposed Rats.
$14,805: Dec. 1985 - Aug. 1986, Principal Investigator Curriculum Vitae
Kehrer, J.P.
Page 3

14. University of Texas Research Institute. "Reoxygenation Injury in Isolated Perfused Heart".
$4,500: Oct. 1, 1986 - March 31, 1987, Principal Investigator 15. General Motors Research Institute. "Oxidant Exposure and Pulmonary Fibrosis". $10,274: Oct. 1987 - Aug. 1988, Principal Investigator 16. National Institutes of Health (NHLBI). "Toxic Lung Damage and the Effect of Steroid Treatment" Research Career Development Award $237,500: Sept. 1, 1984 - Aug. 31, 1989.
17. Burroughs Wellcome Fund. Wellcome Visiting Professorship for Dr. Helmut Sies, $2500 January, 1990, initiator for this award.
18. General Motors Research Institute. "Oxidant Exposure and Pulmonary Fibrosis". $13,699: Jan. 1989 - Dec. 1989, Principal Investigator 19. University of Düsseldorf. "Mitochondrial function under defined conditions of hypoxia".
6000DM: May 9, 1990 - June 30, 1990, Principal Investigator 20. Marnac Corporation. "Antifibrotic activity of pirfenidone" $2,000, May 1, 1990 - Aug. 31, 21. College of Pharmacy BRSG Grant. "Chloroethyl 3H labeled cyclophosphamide" $2000, Jan.
22. Marnac Corporation. "Antifibrotic activity of pirfenidone" $2,100, Dec. 1, 1990 - April 30, 23. Clinitec Nutrition. "Effect of glutathione esters on hypoxic heart injury" $5,000: Aug. 1, 1991- 24. National Institutes of Health (NHLBI). "Toxicity of cardiac hypoxia and reoxygenation".
$131,882: Dec. 1, 1988 - Nov. 30, 1991, Principal Investigator 25. American Cancer Society. "Activation of cyclophosphamide via cooxidation" $124,220: July 1, 1992-June 30, 1994, Principal Investigator (duplicate award to NIH so funds not provided) 26. Dermigen Corp. "Effect of antioxidants on hepatotoxicity of endrin and dieldrin" $6,249: February 1, 1992 - August 31, 1992, Principal Investigator 27. Dermigen Corp. "Effect of antioxidants on hepatotoxicity of endrin and dieldrin" $11,019: September 1, 1992 - December 31, 1992, Principal Investigator 28. Gustavus and Louise Pfeiffer Research Foundation. "Prevention of lung injury induced by the anticancer drug cyclophosphamide" $30,000: Feb. 1991-Feb. 1993, Principal Investigator.
29. National Institutes of Health (NHLBI). "Lung Toxic Interactions Involving Therapeutic Drugs". $351,425: April 1, 1987 - March 31, 1993, Principal Investigator 30. Pharmaceutical Manufacturers Association. Postdoctoral award to Sarath Kanekal "Peroxidase- mediated metabolism of cyclophosphamide". $31,175: July 1, 1992 - June 30, 1993.
31. HealthQuest "General support" $6,000: January - December, 1993; Principal Investigator32. RJR. "Oxidative stress, thiol redox status and cellular senescence". $22,500: Jan. 1, 1997-Dec.
33. NIEHS Center Grant Pilot Project. "Mechanisms of apoptosis: lipoxygenase enzymes and bcl protooncogenes". $13,500: July 1, 1997 – June 30, 1998, Principal Investigator 34. NIEHS Center Grant Pilot Project. "Effect of acrolein on gene expression". $15,000: July 1, 1999 – June 30, 2000, Principal Investigator 35. National Institutes of Health (NHLBI). "Cellular reducing equivalents and oxidative stress".
$653,993: August 1, 1994 - July 31, 2000, Principal Investigator 36. National Institutes of Health (NHLBI). "Mechanisms of cyclophosphamide toxicity".
$399,234: Dec. 1, 1995 - Nov. 30, 2000, Principal Investigator 37. National Institutes of Health (NIEHS). "Mechanisms of acrolein on proliferation and apoptosis". $558,017: Aug. 1, 1999 - July 31, 2003, Principal Investigator B. Current Funding
1.
National Institutes of Health (NCI). "Apoptosis, 5-lipoxygenase activating protein, and bcl-x ".
$900,000: June 1, 2000 - May 31, 2005, Principal Investigator NIEHS. "Mechanisms and prevention of environmental disease". Center Grant$3,000,000: April 1, 1996 - March 31, 2001, Director Research Core 1 1996; AssociateDirector, Austin, 1997-present NIEHS. “Mechanisms of organ-specific toxicology of xenobiotics. Training Grant$320,000; annual costs 7/1/2000-6/30/2003, Training faculty Curriculum Vitae
Kehrer, J.P.
Page 4

Journal Editorial Appointments
Editor for the Americas and Japan - Toxicology Letters (1993-present)
Associate Editor for Reviews - Toxicology Letters (1988-93)
Associate Editor - Journal of Toxicology and Environmental Health (1992-93)
Deputy Chairman of the Editorial Board - Biochemical Journal (2000-present)
Toxicology (1982-1993)Toxicology and Applied Pharmacology (1989-present)Biochemical Journal [editorial advisory panel] (1991-1993)Biochemical Journal (1993-2000)Archives of Biochemistry and Biophysics (2003-present) National and International Invited Research Lectures and Symposium Participation
1.
"Butylated Hydroxytoluene Induced Pulmonary Toxicity" Dept. of Pharmacology andToxicology, Purdue University, West Lafayette, IN, Nov. 1979 "Butylated Hydroxytoluene Lung Toxicity and the Development of Pulmonary Fibrosis" Dept.
of Pharmacology, Southern Illinois Univ. School of Medicine, Springfield, IL, Jan. 1980 "Collagen Metabolism During the Development of Pulmonary Fibrosis"Los Alamos Scientific Laboratory, Los Alamos, NM, Nov. 1980 "Research Frontiers in Pharmacology" Texas Junior Science, Engineering, and HumanitiesSymposium, Joe C. Thompson Conference Center, Austin, TX, Feb. 1981 "Mediators of Lung Toxicity: Activated Metabolites and Oxygen Radicals" Symposium onCellular Mechanisms of Toxicity, Fifth Annual Meeting of Texas Pharmacologists, Lubbock,TX, May, 1981 "The Effect of Butylated Hydroxytoluene on Pulmonary Collagen" Department ofPharmacology, The University of Iowa, Iowa City, IA, October, 1981 "Collagen Synthesis After Acute Lung Damage" College of Pharmacy, University ofWisconsin, Madison, WI, May, 1982 "Paraquat Induced Lung Damage" Abbott Laboratories, North Chicago, IL, August, 1982 "Effects of Corticosteroids on Collagen in Damaged Lung" The Univ. of Texas SystemCancer Center, Smithville, TX, February, 1983 10. "A Comparison of Ranitidine and Cimetidine" Capital Area Pharmacists Association, Austin, 11. "Effects of Corticosteroids on Acutely Damaged Lung" Dept. of Radiation Biology and Biophysics, University of Rochester Medical Center, Rochester, NY, January, 1984 12. "What's New In Therapeutic Drugs" UT Ex-Students Association - Update 84, Austin, TX, 13. "Measuring Collagen Metabolism in Normal and Damaged Lung Tissue" Biomedical Sciences Dept., General Motors Research Labs, Warren, MI, October, 1984 14. "New Developments in Therapeutic Drugs" Texas Society of Professional Engineers, Austin, 15. "Drug-Induced Lung Damage: Models and Mechanisms" Institut für Physiologische Chemie I, Universität Düsseldorf, Düsseldorf, West Germany, February, 1986.
16. "Reactive Oxygen Species in Biological Systems" Institut Für Anorganische Chemie, Universität Basel, Basel, Switzerland, June, 1986.
17. "Reactive Oxygen in Biological Systems" Martin Luther Universität, Sektion Pharmazie, Halle, East Germany, June, 1986.
18. "Models and Mechanisms of Drug-Induced Lung Damage" Universität Göttingen, Institut für Pharmakologie und Toxikologie, Göttingen, West Germany, July, 1986.
19. "Absence of Changes in Xanthine Oxidase During Hypoxia and Reoxygenation of Isolated Rat Heart". Discussion meeting on "The Role of Oxygen Radicals in CardiovascularDiseases", Asolo, Italy, December, 1986.
Curriculum Vitae
Kehrer, J.P.
Page 5

20. "The Oxygen Paradox: A German Experience". Institut Für Physiologische Chemie I, Universität Düsseldorf, Düsseldorf, West Germany, December, 1986.
21. Invited discussant to the workshop on "Antioxidant Interactions", part of the workshop on "Oxygen Radicals and Antioxidants in Cancer and Aging". Univ. California, Berkeley,February, 1987.
22. "Antioxidants in Muscular Dystrophy" Invited speaker, Gordon Research Conference on "Oxy Radicals in Biology and Medicine", Santa Barbara, CA, February, 1987.
23. "Reoxygenation Injury: Energy or Radicals?" Department of Kinesiology, The University of 24. "Overview of The Role of Free Radicals in Pathogenesis" Chairman of the symposium by the same name at the 1988 annual Meeting of the Society of Toxicology, Dallas, TX, Feb. 1988.
25. "Is Oxidative Stress a Factor in Muscular Dystrophy or Cardiac Reperfusion Injury?" Dept. of Pharmacology, College of Pharmacy, The Univ. of Arizona, Tucson, AZ, March 1988.
26. "Energy-Dependence of Enzyme Release From Hypoxic Isolated-Perfused Rat Heart Tissue." Department of Biochemistry, University of Osaka Medical School, Osaka, Japan. April 1988.
27. "Cardiac Reperfusion Injury: Oxidative Changes and Protection by Ruthenium Red." Johnson & Johnson, New Brunswick, NJ, May 1989.
28. "Oxidative Stress in Hypoxic Heart Tissue" Dept. of Physiology & Pharmacology, Texas A & M University Veterinary School, College Station, TX, October 1989.
29. "Hypoxic Heart Injury: Oxidative Stress and Protection by Ruthenium Red" Section of Cardiovascular Sciences, Baylor College of Medicine, Houston, TX December 1989.
30. "Chemical-Induced Lung Injury and Fibrosis" Univ. of British Columbia, School of Medicine, Vancouver, BC, Canada, February 1990.
31. "Mechanisms of Hypoxic Cell Injury: Introduction and Overview" Chairman of the symposium by the same name at the 1990 annual Meeting of the Society of Toxicology,Miami, FL, February 1990.
32. "Free Radicals In Muscular Dystrophy" invited speaker for a symposium on "Chemical Stimulation of Free Radical Mechanisms of Tissue Injury, American Chemical Societymeeting, Boston, MA April 1990.
33. "Oxidative Stress During Cardiac Hypoxia" Institut of Physiological Chemistry I, University of Düsseldorf, Federal Republic of Germany, May 1990.
34. "Cooxidation as the Mechanism of Cyclophosphamide-Induced Lung Injury" Institute of Toxicology, University of Würzburg, Federal Republic of Germany, May 1990.
35. "Cooxidation as a Mechanism of Cyclophosphamide Bioactivation" Department of Pharmacology, College of Medicine, Texas A & M University, February 1991.
36. "The Mechanism of Cyclophosphamide-Induced Lung Injury: Cooxidation versus P450" Dept. Pharmacology & Toxicology, College of Medicine, West Virginia University, March1991.
37. "Cooxidation and Hypoxia: Pathways Leading to Reactive Species and Tissue Injury" Dept. of Pharmacology /Toxicology, College of Pharmacy, Northeast Lousiana Univ., April 1991.
38. "Oxidative Stress During Hypoxia: Excess Radicals or Compromised Defenses", Symposium on Free Radicals and Oxidative Stress, Gulf Coast Society of Toxicology meeting, SciencePark, TX October 1991.
39. "Cooxidation of Cyclophosphamide: Does it Lead to Lung and Bladder Toxicity?" University of California, Davis, February 1992.
40. "Redox balance of the hypoxic heart" Univ. Oklahoma, College of Pharmacy, May, 1992.
41. "Effects of oxygen deprivation on cardiac redox systems" Symposium on Molecular Mechanisms of Ischemia/Reperfusion Injury, Western Pharmacology Society, Incline Village,NV, Feb. 1993 42. "Oxidant toxicity in hypoxic heart tissue", Dept. of Biological Sciences, Southern Methodist 43. "The science of toxicology", LBJ High School Science, Mathematics and Technology Curriculum Vitae
Kehrer, J.P.
Page 6

44. "Oxidative stress and the supply of cellular reducing equivalents", Penn State's Thirteenth Summer Symposium in Molecular Biology" Molecular and Cellular Mechanisms of Toxicity.
University Park, PA, August 1994.
45. "Reducing mitochondrial oxidative stress", Dept. of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, January 1995.
46. "Reducing mitochondrial oxidative stress", Dept. of Pharmacology and Toxicology, School of Pharmacy, Purdue University, W. Lafayette, IN, January 1995.
47. "Bcl-2 and free radicals, and reducing mitochondrial oxidative stress" Dept. of Pathology, University of Texas Medical Branch, Galveston, TX, August, 1995.
48. "Oxidative stress: Mitochondrial responses and the role of bcl-2" Dept. of Pharmaceutical Chemistry, Wayne State University, Detroit, MI, August, 1995.
49. "NIH Grant Writing", Northeast Louisiana University, October 1995.
50. "Oxidative stress, reducing equivalents and bcl-2" Zeneca Pharmaceuticals, Macclesfield, 51. "Oxidative stress, reducing equivalents and bcl-2" MRC Toxicology Unit, Leicester, England, 52. "Oxidative stress, reducing equivalents and bcl-2" Univ. Düsseldorf, Germany, June 199653. "Oxidative stress, reducing equivalents and bcl-2" Leiden University, Center for Drug Research, Division of Molecular Pharmacology, Amsterdam, The Netherlands, June 1996 54. "Acrolein mercapturates: A factor in cyclophosphamide toxicity?" University of Würzburg, 55. "Oxidants, antioxidants and the Bcl protooncogenes" University of Düsseldorf, Germany, May 56. "Oxidants, antioxidants and the Bcl protooncogenes" University of Konstanz, Germany, June 57. "Oxidants, antioxidants and the Bcl protooncogenes" University of Zurich, Switzerland, June 58. "Lipoxygenase and bcl-xL in apoptotic cell death" University of Houston, December 1997.
59. "5-Lipoxygenase activator protein and bcl-xL in apoptotic cell death" Essen University, 60. "5-Lipoxygenase activating protein (FLAP), bcl-xL and apoptosis" Washington State 61. "5-Lipoxygenase activating protein (FLAP), bcl-xL and apoptosis" Penn State University, 62. "Overview of current research: FLAP and Apoptosis; Acrolein and NF-κB, Proteasome and hsp70" Oklahoma State University, December 1998.
“Detoxification” Plenary lecture at the NIH workshop on Cellular Responses to Low Dosesof Ionizing radiation, Bethesda, MD April 1999.
"The cause-effect of oxidative stress and apoptosis". Symposium presentation at the annualmeeting of the Teratology Society. Keystone, CO, July 1999.
65. "Basic concepts of toxicology" American Chemical Society Short Course; Washington DC, Sept. 1999; New Orleans, November 1999; San Francisco, April 2000; Boston, August 2000,Washington DC, August 2000 66. “The Haber-Weiss reaction and mechanisms of toxicity” Workshop presentation at the annual meeting of the Society of Toxicology. Philadelphia, PA, March 2000 67. “Energy malmetabolism, oxidative stress and toxicological consequences in the heart” Continuing education presentation at the annual meeting of the Society of Toxicology.
Philadelphia, PA, March 2000 68. "Unexpected pathways for xenobiotic-induced apoptosis; focus on lipoxygenase inhibitors" Texas A&M University, September 2000.
69. “Death becomes her: Pathways to apoptosis”, presentation to Women in Science, Austin, TX 70. “Acrolein and apoptosis; NF-κB, AP-1 and caspases”, Distinguished Speaker in Environmental Cardiology, University of Louisville, KY, August 2001.
Curriculum Vitae
Kehrer, J.P.
Page 7

71. “Introduction to thioredoxins and thioredoxin reductases: central roles in toxicity and cancer”, symposium chaired at 2002 annual meeting of the Society of Toxicology 72. Chairman, Session 1, Symposium on “Oxidative stress: health benefits of micronutrients”, L’Abbaye de Royaumont, Paris, France, July 2002.
73. "Lipocalins, PPARs and apoptosis", Marshall University, Huntington, West Virginia, April 74. "Acrolein, transcription factors and thioredoxin", Wake Forest University, November 2003.
75. "Lipocalins and apoptosis", Symposium presentation at the annual Society of Toxicology 76. "NSAIDs, Peroxisome Proliferators and apoptosis: any role for oxidants?" North Carolina 77. "The Balance Between Life and Death Signaling", Purdue University, November 2004.
Curriculum Vitae
Kehrer, J.P.
Page 8

TEACHING
Students
Postdoctoral Fellows:
National Science Foundation and Howard Hughes Summer Students NIH Minority High School Student Research Apprentice Program: Erika Kappe, 1992; Felecia Special Topics Graduate Students:
Special Topics Undergraduate Students:
Other Students
Fariba Moraghebi, 2001; M.S. graduate student from Sweden Graduate Students Supervised:
Thomas Paraidathathu, 1982-84 (M.S. June 1984); 1989-93 (Ph.D. August 1993)Michael E. Murphy, 1985-88 (Ph.D. May, 1988)Younja Park, 1985-1989 (M.S., May 1987; Ph.D. December 1989)Robin Smith, 1984-90 (Ph.D., August 1990)Jairam Palamanda, 1988-92 (Ph.D., August 1992)Lucy Fraiser, 1989-92 (Ph.D., December 1992)Whayoung Lee, 1990-1993 (co-supervisor) Ph.D., December 1993Camarie S. Perry, 1992-1995 (M.S. May 1995)Hanlin Liu, 1992-1995 (M.S. May 1995)Xiang Feng, 1996-1998 (M.S., August 1998)John Robertson, 1995-1999 (Ph.D., May 1999)Julie Kern, 1998-2002 (Ph.D., December 2002)Jonathan Pabalan, 1999-2000 (M.S. December 2000)George Acquaah-Mensah, 1998-2001 (Ph.D., August 2001)Vaidehee Deshpande, 2000-presentElisa Atarod, 2001-2003 (M.S., December 2003)Young Eun Choi, 2001-present Curriculum Vitae
Kehrer, J.P.
Page 9

Shreya Metra, 2002-presentDmitriy Ovcharenko, 2004-present Masters Thesis Committees
Sedelia Lopez; Physical & Health Education, M.S. May 1983 (no thesis)Jon Swift; Kinesiology, M.S. May, 1996Hae-Seong Yoon, M.S., August 1999 Ph.D. Dissertation Committees
Kenneth S. Santone; Pharmacology - Ph.D. 1984Lee James Carmack; Biomedical Engineering - Ph.D. 1987Glen Kisby; Pharmacology - Ph.D. 1986Donald R. Needham-VanDevanter; Medicinal Chemistry - Ph.D. 1986John Swann; Pharmacology - Ph.D. 1989Tina Machu; Pharmacology - Ph.D. 1990Robert W. Reed; Biochemistry - Ph.D. 1990Barbara Hill; Pharmacology - Ph.D. 1991A.D. Gurusinghe - Ph.D. 1989; Monash Univ., Clayton, Melbourne, AustraliaRiq Chacon; Pharmacology - Ph.D. 1991Douglas W. Bowles; Kinesiology - Ph.D. 1992Roberta Grant; Pharmacology - Ph.D. 1994Steven Seiler; Kinesiology - Ph.D. 1995Shujia Pan; Pharmacology - Ph.D., 1994Richard Timothy Miller; Pharmacology - Ph.D., 1996Heather Kliner; Pharmacology - Ph.D., 1996Brennan Harris; Kinesiology - Ph.D. 1999Kelly Towndrow; Pharmacology – Ph.D., 2000Qihong Huang; Pharmacology - Ph.D., 2000Xiang Jing; Nutrition - Ph.D., 2001John Giammona; Pharmacology – Ph.D. 2002John Kern: Medicinal Chemistry – Ph.D. 2002Lora Watts; Pharmacology San Antonio – Ph.D. 2004Ryan Taylor, Kinesiology, Ph.D. 2004Bobby Bhatia; MD Anderson, Science Park – Ph.D. activeYamini Chandrasekaran; Pharmacology – Ph.D. active Courses Taught
Iowa
1977 - Pharmacology 71:120 (Drugs; Their Nature Action and Use) course coordinator.
Texas
Undergraduate
1980-1984 and
PHR 373N (Pharmacology III) course coordinator alternate semesters; responsible for 50% of the course each semester including summers.
PHR 173L (Pharmacology Laboratory) 13% of the course 3 times yearly.
PHR 362L (Toxicology of Modern Drugs): 20% of the course each semester.
PHR 362M (experimental toxicology): 20% of the course each Fall.
PHR 348 (New drugs & New drug developments) 100% of the course PHR 473M (Pharmacology II) 25% of course each semester.
Pharmacotherapeutics IIb; 15% of course each year.
Curriculum Vitae
Kehrer, J.P.
Page 10

GraduateSeminar in Pharmacology: each long semesterToxicological Methods: 15% of the course in Fall or SpringAdvanced Toxicology): 20% of course each year through 1990.
Biochemical & Molecular Toxicology: 20% of the course each Spring.
Biomedical Pharmacology: 25% of course each Fall, 1998-present Teaching Honors
Nominated for Pharmacy teaching excellence award, Texas, 1981.
1. Consultant to the Legislative Task Force on Cancer in Texas, 1984.
2. Director, Travis County Water District #18, 2002-present Research Evaluation Committee for the Texas Junior Science, Engineering, and Humanities Symposium: 1982-1983 University Research Institute grant review committee: 1987-1990.
Research Safety Advisory Committee: 1991 - 1997.
1. Admissions: 1980-1982; 1988-19902. Continuing Education: 1980-19843. Graduate Studies Committee: 1980-present4. Recruitment Subcommittee; Graduate Studies Committee: 1980-83 (Chairman 1980-82)5. Advisory Subcommittee on Equipment Purchases: 19816. Advisory Subcommittee on Teaching Assistantships: 19827. Baccalaureate Curriculum Committee for the Accreditation Review: 19828. Curriculum Committee: 1982 - 19849. Administrative subcommittee of the Graduate Studies Committee: 1984-198910. Financial aid committee: 1985-present; chairman 1988-present11. Departmental Review Committee on Human Research: 1986-198812. Equipment Committee: 1986-1988 (chairman)13. Financial Resources Subcommittee of the Accreditation Review Committee: chairman,198914. Faculty Development Committee: 1990-199315. Pharm.D. Degree Structure Steering Committee: 1990-1991.
16. Space Committee: 1990-1994 , 1999-2000 (chairman)17. All College Seminar Committee: 1994-199618. Graduate Financial Aid Committee: 2000-200219. Library Services Committee, 2000-2002.
20. Executive Committee (promotion and tenure); 1990-present; chair 2002-200321. PharmD/PhD task force (chairman) 2001.
22. Accreditation Self-Study: financial resources (chairman), Steering Committee (member), College Missions and Goals (member) 2002-2003.
23. Task Force on Pharmacy Enrollment (chairman) 2004 1. Public Relations Committee - Mechanisms Section Society of Toxicology: 1983 - 19842. Chairman, General Toxicology session, Society of Toxicology, 24th Annual Meeting, 1985.
3. Member, Committee on Public Communications, Society of Toxicology, 1985 - 19884. Chairman, Symposium on "Free Radical Mechanisms in Pathogenesis" Society of Toxicology, 27th Annual Meeting, 1988.
Curriculum Vitae
Kehrer, J.P.
Page 11

5. Chairman, Pulmonary Toxicology session, Society of Toxicology 28th Annual Meeting, 6. Chairman, Society of Toxicology Continuing Education Course on "Free Radical Toxicology", 29th annual meeting, 1990.
7. Chairman and organizer, Symposium on "Mechanisms of Hypoxic Cell Injury" Society of8. Toxicology, 29th Annual Meeting, 1990.
9. Awards Committee, Society of Toxicology, 1990-1992.
10. Councilor, Mechanisms Specialty Section, Society of Toxicology, 1992-1994.
11. Society of Toxicology Ad hoc Chlorine Working Group. 1994. Work resulted in the publication of: "Toxicologic principles do not support the banning of chlorine: A Society of
Toxicology Position Paper" Fundam. Appl. Toxicol. 24: 1-2 (1995).
12. Member, Board of Publications, Society of Toxicology, 1995-1999.
13. Member, Nominating Committee, Oxygen Society, 1995-1996.
14. President, Mechanisms Specialty Section, Society of Toxicology, 1998-1999.
15. Society of Toxicology Media Resource Specialist, 1997-1999.
16. Society of Toxicology World-Wide-Web task force, 1997-200017. Society of Toxicology – elected to Nominating Committee, 200018. Society of Toxicology World-Wide-Web Special Advisory Committee, 2001-2005 19. American Society for Pharmacology and Experimental Therapeutics, elected Chairman of Miscellaneous Scholarly Activities
1. Rho Chi Faculty Advisor, 1981-1983.
2. Item writer for the National Association of Boards of Pharmacy Licensure Examinations,
3. Co-author (with Daniel M. Kehrer) of "Consumer Drug File"--A syndicated drug information 4. Invited participant, Pharmaceutical Manufacturers Association Coordinated Industry Program for Pharmacy Faculty, Abbott Laboratories, August 16-27, 1982.
Grant and other Review Activities
1. Veterans Administration, Merit Review Board for the Basic Sciences, 1983.
2. Research Corporation Cottrell College Science Grants, 1988, 1989.
3. University of Texas Research Institute, 1987-1990
4. Special Reviewer, NIH Toxicology Study Section, Oct. 1989.
5. Member NIH Toxicology Study Section, July 1991 - June 1995.
6. American Institute of Biological Sciences (for U.S. Army), 1995.
7. Oral Cancer Center Review Panel, NIH, 1996
8. ALTOX NIH Study Section, Ad hoc; 1996, 1997, 1999, 2002
9. External reviewer, Graduate Center for Toxicology, University of Kentucky, April 1996
10. National Science Foundation, 1996
11. John Sealy Memorial Endowment Fund, Univ. Texas Med. Branch Galveston, 1996.
12. Veterans Administration, Pulmonary Merit Review Board, member 1997-1998.
13. Pacific Northwest National Laboratory, Environmental Health Initiative Aug. 1999.
14. Medical Center Research Fund grants, Univ. Kentucky, 200115. Israel Biomedical Research Grant Program reviewer, 2001, 200216. Philip Morris External Research Program reviewer, 2001, 2002.
17. EPA FIFRA Scientific Advisory Panel. 2003-200618. Member, External Advisory Board for the University of Colorado NIEHS Toxicology Training Grant (grant submitted 5/04).
19. Member, External Advisory Committee for the Department of Pharmacology and Toxicology, University of Utah, Feb. 2005.
Curriculum Vitae
Kehrer, J.P.
Page 12

PUBLICATIONS
1. Hornemann, U., Kehrer, J.P. and Eggert, J.H.: Pyruvic acid and D-glucose as precursors in mitomycin biosynthesis by Streptomyces verticillatus. J. Chem. Soc. Chem. Commun. 1045-1046 (1974).
2. Hornemann, U., Kehrer, J.P., Nunez, C.S. and Ranieri, R.L.: D-Glucosamine and L-citrulline, precursors in mitomycin biosynthesis by Streptomyces verticillatus. J. Amer. Chem. Soc. 96:
320-322 (1974).
3. Hornemann, U., Kehrer, J.P., Nunez, C.S., Ranieri, R.L. and Ho, Y.K.: Precursors in mitomycin biosynthesis by Streptomyces verticillatus, in "Developments in IndustrialMicrobiology", Vol. 15, pp. 82-92 (1974).
4. Kehrer, J.P. and Autor, A.P.: Age-dependent lipid peroxidation in neonatal rat lung tissue.
Arch. Biochem. Biophys. 181: 73-81 (1977).
5. Kehrer, J.P. and Autor, A.P.: Changes in the fatty acid composition of rat lung lipids during development and following age-dependent lipid peroxidation. Lipids 12: 596-603 (1977).
6. Kehrer, J.P. and Autor, A.P.: The relationship between fatty acids and lipid peroxidation in lungs of neonates. Biol. Neonate 34: 61-67 (1978).
7. Kehrer, J.P. and Autor, A.P.: The effect of dietary fatty acids on the composition of adult rat lung lipids: relationship to oxygen toxicity. Toxicol. Appl. Pharmacol.44: 423-430 (1978).
8. Kehrer, J.P., Haschek, W.M. and Witschi, H.P.: The influence of hyperoxia on the acute toxicity of paraquat and diquat. Drug Chem. Toxicol. 2: 397-408 (1979).
9. Kehrer, J.P. and Witschi, H.P.: Effects of drug metabolism inhibitors on butylated hydroxy- toluene-induced pulmonary toxicity in mice. Toxicol. Appl. Pharmacol. 53: 333-342 (1980).
10. Kehrer, J.P. and Witschi, H.P.: In vivo collagen accumulation in an experimental model of pulmonary fibrosis. Exp. Lung Res. 1: 259-270 (1980).
11. Kehrer, J.P.: Oxygen-Induced Lung Damage I. Chemistry of oxygen reduction, in "Lectures in Toxicology", ed. G. Zbinden, Pergamon Press (1981).
12. Kehrer, J.P.: Oxygen-Induced Lung Damage II. Pulmonary oxygen toxicity, in "Lectures in Toxicology", ed. G. Zbinden, Pergamon Press (1981).
13. Kehrer, J.P. and Witschi, H.P.: The effect of indomethacin, prednisolone, and cis-4- hydroxyproline on pulmonary fibrosis produced by treatment with butylated hydroxytoluene
and oxygen. Toxicology 20: 281-288 (1981).
14. Witschi, H.P., Hakkinen, P.J. and Kehrer, J.P.: Modification of lung tumor development in A/J mice. Toxicology 21: 37-45 (1981).
15. Witschi, H.P. and Kehrer, J.P.: Adenoma development in mouse lung following treatment with possible promoting agents. J. Amer. Coll. Toxicol. 1: 171-184 (1982).
16. Kehrer, J.P.: Collagen production rates following acute lung damage induced by butylated hydroxytoluene. Biochem. Pharmacol. 31: 2053-2058 (1982).
Curriculum Vitae
Kehrer, J.P.
Page 13

17. Kehrer, J.P. and Autor, A.P.: Unsaturated fatty acids in the postnatally developing rat lung.
Lipids 18: 50-54 (1983).
18. Haschek, W.M., Reiser, K.M., Klein-Szanto, A.J.P., Kehrer, J.P., Smith, L.H., Last, J.A. and Witschi, H.P.: Potentiation of butylated hydroxytoluene-induced acute lung damage by
oxygen. Cell kinetics and collagen metabolism. Am. Rev. Respir. Dis. 127: 28-34 (1983).
19. Kehrer, J.P.: The effect of BCNU (carmustine) on tissue glutathione reductase activity.
Toxicol. Lett. 17: 63-68 (1983).
20. Kehrer, J.P., Pearlman, R. and Smith, M.A.: Direct effects of corticosteroids on in vitro collagen production by normal and damaged lung tissue. Toxicology 28: 235-246 (1983).
21. Kehrer, J.P. and Paraidathathu, T.: Enhanced oxygen toxicity following pretreatment with BCNU. Fundam. Appl. Toxicol. 4: 760-767 (1984).
22. Kehrer, J.P., Klein-Szanto, A.J.P., Sorensen, E.M.B., Pearlman, R. and Rosner, M.H.: Enhanced acute lung damage following corticosteroid treatment. Am. Rev. Respir. Dis. 130:
256-261 (1984).
23. Kehrer, J.P. and Dydek, S.T.: Analysis of pulmonary collagen production by HPLC separation of radiolabeled hydroxyproline and proline. Proc. West. Pharmacol. Soc. 27: 319-322 (1984).
24. Dydek, S.T. and Kehrer, J.P.: Effects of sodium chloride on the HPLC separation of hydroxyproline and proline. LC 2: 536-538 (1984).
25. Kehrer, J.P.: Collagen synthesis and degradation in acutely damaged mouse lung tissue following treatment with prednisolone. Biochem. Pharmacol. 34: 2519-2524 (1985).
26. Paraidathathu, T., Combs, A.B. and Kehrer, J.P.: In vivo effects of 1,3-bis(2-chloroethyl)- 1- nitrosourea and doxorubicin on the cardiac and hepatic glutathione systems. Toxicology 35:
113-124 (1985).
27. Kehrer, J.P. and Kacew, S.: Systemically applied chemicals that damage lung tissue.
Toxicology 35: 251-293 (1985).
28. Kehrer, J.P. and Klein-Szanto, A.J.P.: Enhanced acute lung damage in mice following administration of 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 45: 5707-5713 (1985).
29. Lee, Y-C. C. and Kehrer, J.P.: Increased pulmonary collagen synthesis in mice treated with cyclophosphamide. Drug Chem. Toxicol. 8: 503-512 (1985).
30. Kehrer, J.P., Lee, Y-C.C. and Solem, S.M.: Comparison of in vitro and in vivo rates of collagen synthesis in normal and damaged lung tissue. Exp. Lung Res. 10: 187-201 (1986).
31. Murphy, M.E. and Kehrer, J.P.: Activities of antioxidant enzymes in the muscle, liver and lung of chickens with inherited muscular dystrophy. Biochem. Biophys. Res. Commun. 134: 550-
556 (1986).
32. Kehrer, J.P., Lee, Y-C.C. and Smith, R.D.: Effect of intratracheally administered anticancer drugs on lung hydroxyproline content. Toxicol. Lett. 30: 63-70 (1986).
33. Murphy, M.E. and Kehrer, J.P.: Free radicals: A potential pathogenic mechanism in inherited muscular dystrophy. Life Sci. 39: 2271-2278 (1986).
Curriculum Vitae
Kehrer, J.P.
Page 14

34. Kehrer, J.P., Klein-Szanto, A.J.P., Thurston, D., Lindenschmidt, R.C. and Witschi, H.R.: O,S,S-Trimethyl phosphorodithioate-induced lung damage in rats and mice. Toxicol. Appl.
Pharmacol.
84: 480-492 (1986).
35. Kehrer, J.P.: Oxygen, in "Handbook on Toxicity of Inorganic Compounds", (H.G. Seiler and H. Sigel, eds.), Marcel Dekker, NY, pp. 505-515 (1987).
36. Kehrer, J.P., Piper, H.M. and Sies, H.: Xanthine oxidase and reoxygenation injury in isolated perfused rat heart. Free Rad. Res. Commun. 3: 69-78 (1987).
37. Murphy, M.E. and Kehrer, J.P.: Simultaneous measurement of tocopherols and tocopheryl quinones in tissue fractions using HPLC with redox-cycling electrochemical detection. J.
Chromatog.
421, 71-82 (1987).
38. Kehrer, J.P. and Lee, Y-C.C.: Pulmonary hydroxyproline content and production following treatment of mice with O,S,S- trimethyl phosphorodithioate. Toxicol. Lett. 38: 321-327 (1987).
39. Wright, E.S., Kehrer, J.P., White, D.M. and Smiler, K.L.: Effects of chronic exposure to ozone on collagen in rat lung. Toxicol. Appl. Pharmacol. 92: 445-452 (1988).
40. Kehrer, J.P., Sevanian, A., Trush, M.A., Mossman, B.T. and Smith, M.T.: Free radical mechanisms in chemical pathogenesis. Toxicol. Appl. Pharmacol. 95: 349-362 (1988).
41. Kehrer, J.P., Park, Y. and Sies, H.: Energy-dependence of enzyme release from hypoxic isolated-perfused rat heart tissue. J. Appl. Physiol. 65: 1855-1860 (1988).
42. Murphy, M.E. and Kehrer, J.P.: Increased oxidation of tocopherols in chickens with inherited muscular dystrophy, in "Oxygen Radicals in Biology and Medicine", Vol. 49, The Proceedingsof the Fourth International Congress on Oxygen Radicals, (M. G. Simic, K.A. Taylor, J.F.
Ward, and C. von Sonntag, eds.), Plenum, New York, pp. 611-614 (1988).
43. Park, Y., Smith, R.D., Combs, A.B. and Kehrer, J.P.: Prevention of acetaminophen-induced hepatotoxicity by dimethyl sulfoxide. Toxicology 52: 165-175 (1988).
44. Kehrer, J.P.: Cardiac cell breakdown at reoxygenation: Absence of changes in xanthine oxidase and effects of calcium concentration, in "The Role of Oxygen Radicals inCardiovascular Diseases", (A. L'Abbate and F. Ursini, eds.), Kluwer Academic Publishers,Dordrecht, pp. 71-89 (1988).
45. Murphy, M.E. and Kehrer, J.P.: Lipid peroxidation inhibitory factors in liver and muscle of rat, mouse and chicken. Arch. Biochem. Biophys. 268: 585-593 (1989).
46. Murphy, M.E. and Kehrer, J.P.: Oxidative stress and muscular dystrophy. Chemico-biol. Interact. 69: 101-173 (1989).
47. Kehrer, J.P.: Concepts related to the study of reactive oxygen and cardiac reperfusion injury.
Free Radical Res. Commun. 5: 305-314 (1989).
48. Murphy, M.E. and Kehrer, J.P.: Oxidation state of tissue thiol groups and content of protein carbonyl groups in chickens with inherited muscular dystrophy. Biochem. J. 260: 359-364
(1989).
49. Murphy, M.E. and Kehrer, J.P.: Altered contents of tocopherols in chickens with inherited muscular dystrophy. Biochem. Med. Metab. Biol. 41: 234-245 (1989).
Curriculum Vitae
Kehrer, J.P.
Page 15

50. Starnes, J.W., Cantu, G., Farrar, R.P. and Kehrer, J.P.: Skeletal muscle lipid peroxidation in exercised and food restricted rats during aging. J. Appl. Physiol. 67: 69-75 (1989).
51. Kehrer, J.P. and Starnes, J.W.: Models and markers used to study cardiac reperfusion injury.
Pharmacol. Therap. 44: 123-145 (1989).
52. Kehrer, J.P.: Bleomycin and cyclophosphamide toxicity in mice with damaged lung tissue.
Toxicology 57: 69-82 (1989).
53. Ziegler, D.M. and Kehrer, J.P.: Oxygen radicals and drugs: in vitro measurements. Methods in Enzymology 186: 621-626 (1990).
54. Park, Y. and Kehrer, J.P.: Protection against hypoxic injury in isolated-perfused rat heart by ruthenium red. J. Pharmacol. Expt. Ther. 253: 628-635 (1990).
55. Kehrer, J.P. and DiGiovanni, J.: Comparison of lung injury induced in four strains of mice by butylated hydroxytoluene. Toxicol. Lett. 52: 55-61 (1990).
56. Kehrer, J.P.: Commentary on the pulmonary toxicity of inhaled and intravenous talc. Toxicol. Lett. 52: 117-119 (1990).
57. Kehrer, J.P.: Commentary on the production of alveolar macrophage-derived growth regulating proteins in response to lung injury. Toxicol. Lett. 54: 1-2 (1990).
58. Kehrer, J.P., Jones, D.P., Lemasters, J.J., Farber, J.L. and Jaeschke, H.: Mechanisms of hypoxic cell injury. Toxicol. Appl. Pharmacol. 106: 165-178 (1990).
59. Kehrer, J.P. and Park, Y.: Purity of ruthenium red used in biochemical research. J. Pharmacol. Meth. 25: 179-183 (1991).
60. Bowles, D.K., Torgan, C.E., Ebner, S., Kehrer, J.P., Ivy, J.L. and Starnes, J.W.: Effects of acute, submaximal exercise on skeletal muscle vitamin E. Free Rad. Res. Commun. 14: 139-
143 (1991).
61. Kehrer, J.P. and Park, Y.: Oxidative stress during hypoxia in isolated-perfused rat heart. Adv. Exp. Med. Biol. 283: 299-304 (1991).
62. Smith, R.D. and Kehrer, J.P.: Cooxidation of cyclophosphamide as an alternative pathway for its bioactivation and lung toxicity. Cancer Res. 51: 542-548 (1991).
63. Park, Y. and Kehrer, J.P.: Oxidative changes in hypoxic-reoxygenated rabbit heart: A consequence of hypoxia rather than reoxygenation. Free Rad. Res. Commun. 14: 179-185
(1991).
64. Park, Y., Kanekal, S. and Kehrer, J.P.: Oxidative changes in hypoxic rat heart tissue. Am. J. Physiol. 260: H1395-H1405 (1991).
65. Fraiser, L., Kanekal, S. and Kehrer, J.P.: Cyclophosphamide toxicity: characterizing and avoiding the problem. Drugs 42: 781-795 (1991).
66. Seiler, K.S., Kehrer, J.P. and Starnes, J.W.: Effect of perfusion pressure at reoxygenation on reflow and function in isolated rat hearts. Am. J. Physiol. 262: H1029-H1035 (1992).
Curriculum Vitae
Kehrer, J.P.
Page 16

67. Kehrer, J.P. and Murphy, M.E.: Free radicals and muscular dystrophy. in Free Radical Mechanisms of Tissue Injury (C.V. Smith and M. Moslen, eds) CRC Press, Boca Raton, pp.
189-202 (1992).
68. Palamanda, J.R. and Kehrer, J.P.: Inhibition of protein carbonyl formation and lipid peroxidation by glutathione in rat liver microsomes. Arch. Biochem. Biophys. 293: 103-109
(1992).
69. Kehrer, J.P. and Paraidathathu, T.: The use of fluorescent probes to assess oxidative processes in isolated-perfused rat heart tissue. Free Rad. Res. Commun. 16: 217-225 (1992).
70. Kanekal, S., Fraiser, L. and Kehrer, J.P.: Pharmacokinetics, metabolic activation and lung toxicity of cyclophosphamide in C57/Bl6 and ICR mice. Toxicol. Appl. Pharmacol. 114: 1-8
(1992).
71. Spitz, D.R., Kinter, M.T., Kehrer, J.P. and Roberts, R.J.: The effect of monosaturated and polyunsaturated fatty acids on O2-toxicity in cultured cells. Pediatr. Res. 32: 366-372 (1992).
72. Paraidathathu, T., de Groot, H. and Kehrer, J.P.: Production of reactive oxygen by mitochondria from normoxic and hypoxic rat heart tissue. Free Rad.Biol. Med. 13: 289-297
(1992).
73. Fraiser, L. and Kehrer, J.P.: Murine strain differences in metabolism and bladder toxicity of cyclophosphamide. Toxicology 75: 257-272 (1992).
74. Kanekal, S. and Kehrer, J.P.: Evidence for peroxidase-mediated metabolism of cyclophosphamide. Drug Metab. Dispos. 21: 37-42 (1993).
75. Palamanda, J.R. and Kehrer, J.P.: Involvement of vitamin E and protein thiols in the inhibition of microsomal lipid peroxidation by glutathione. Lipids 28: 427-431 (1993).
76. Kehrer, J.P.: Free radicals as mediators of tissue injury and disease. Crit. Rev. Toxicol. 23: 21-
77. Fraiser, L. and Kehrer, J.P.: Effect of indomethacin, aspirin, nordihydroguairetic acid, and piperonyl butoxide on cyclophosphamide-induced bladder damage. Drug Chem. Toxicol. 16:
117-133 (1993).
78. Kehrer, J.P., Paraidathathu, T. and Lund, L.G.: Effects of oxygen deprivation on cardiac redox systems. Proc. West. Pharmacol. Soc. 36: 45-52 (1993).
79. Kehrer, J.P.: Systemic pulmonary toxicity, in "General and Applied Toxicology. Volume 1: Basic, Route and Organ Toxicity", (B. Ballantyne, T. Marrs, and P. Turner, eds.), StocktonPress, New York, pp. 537-554 (1993).
80. Kanekal, S. and Kehrer, J.P.: Metabolism of cyclophosphamide by lipoxygenases. Drug Metab. Dispos. 22: 74-78 (1994).
81. Kehrer, J.P. and Smith, C.V.: Free radicals in biology: sources, reactivities and roles in the etiology of human diseases. in Natural Antioxidants in Human Health and Disease, (B. Frei,ed.) Academic Press, pp.25-62 (1994).
82. Kehrer, J.P. and Lund, L.G.: Cellular reducing equivalents and oxidative stress. Free Rad. Biol. Med. 17: 65-75 (1994).
Curriculum Vitae
Kehrer, J.P.
Page 17

83. Paraidathathu, T., Palamanda, J. and Kehrer, J.P.: Modulation of rat heart mitochondrial function and the production of reactive oxygen by vitamin E deficiency. Toxicology 90: 103-
114 (1994).
84. Lund, L.G., Paraidathathu, T. and Kehrer, J.P.: Reduction of glutathione disulfide and the maintenance of reducing equivalents in hypoxic hearts after the infusion of diamide.
Toxicology 93: 249-262 (1994).
85. Stevenson, D., Kehrer, J.P., Kolaja, K.L., Walborg, E.F.Jr. and Klaunig, J.E.: Effect of dietary antioxidant vitamins on dieldrin-induced hepatotoxicity in mice. Toxicol. Lett. 75: 177-183
(1995).
86. Perry, C.S., Liu, X.L., Lund, L.G., Whitman, C.S. and Kehrer, J.P.: Differential toxicities of cyclophosphamide and its glutathione metabolites to A549 cells. Toxicol. In Vitro 9: 21-26
(1995).
87. Ramu, K., Fraiser, L.H., Mamiya, B., Ahmed, T., and Kehrer, J.P.: Acrolein mercapturates: Synthesis, characterization, and assessment of their role in the bladder toxicity of
cyclophosphamide. Chem. Res. Toxicol. 8: 515-524 (1995).
88. Liu, H. and Kehrer, J.P.: The reduction of glutathione disulfide produced by t-butyl hydroperoxide in respiring mitochondria. Free Rad. Biol. Med. 20: 433-442 (1996).
89. Seiler, K.S., Kehrer, J.P. and Starnes, J.W.: Exogenous glutathione attenuates stunning following intermittent hypoxia in isolated rat hearts. Free Rad. Res. 24: 115-122 (1996).
90. Ramu, K., Perry, C.S., Ahmed, T., Pakenham, G. and Kehrer, J.P.: Studies on the basis for the toxicity of acrolein mercapturates. Toxicol. Appl. Pharmacol. 140: 487-498 (1996).
91. Kehrer, J.P. and Margolin, S.B.: Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol. Lett. 90: 125-132 (1997).
92. Kehrer, J.P.: Mechanisms: Free radicals and reactive oxygen species. In General Principles, Toxicokinetics, and Mechanisms of Toxicity, (J.A. Bond, ed.) Elsevier, Vol. 1 ofComprehensive Toxicology, pp. 275-301 (1997).
93. Ramu, K. and Kehrer, J.P.: The pulmonary toxicity of chemotherapeutic agents. In Toxicology of the Respiratory Tract, (R. Roth, ed.) Elsevier, Vol. 8 of Comprehensive Toxicology, pp.
521-541 (1997).
94. Horton, N.D., Mamiya, B.M. and Kehrer, J.P.: Relationships between cell density, glutathione and proliferation of A549 human lung adenocarcinoma cells treated with acrolein. Toxicology
122: 111-122 (1997).
Bojes, H.K., Datta, K., Xu, J., Chin, A., Simonian, P., Nuñez, G. and Kehrer, J.P.: Bcl-xL overexpression attenuates glutathione depletion in FL5.12 cells following IL-3 withdrawal.
Biochem. J. 325: 315-319 (1997).
Robertson, J.D., Starnes, J.W. and Kehrer, J.P.: Cosubstrates involved in the reduction of
cytosolic glutathione disulfide in rat heart. Toxicology 124: 11-19 (1997).
Robertson, J.D., Datta, K. and Kehrer, J.P.: Bcl-xL overexpression restricts heat-induced apoptosis and influences hsp70, bcl-2 and bax protein levels in FL5.12 cells. Biochem.
Biophys. Res. Commun.
241: 164-168 (1997).
Curriculum Vitae
Kehrer, J.P.
Page 18

Swift, J.N., Kehrer, J.P., Seiler, K.S. and Starnes, J.W.: Changes in vitamin E levels in rat
skeletal muscle and liver after exercise. Int. J. Sport Nutr. 8: 105-112 (1998).
Datta, K., Chin, A., Ahmed, T., Qing, W-G., Powell, K.L., Simhambhatla, P., MacLeod, M.C.
and Kehrer, J.P.: Mixed effects of 2,6-dithiopurine against cyclophosphamide-mediated
bladder and lung toxicity in mice. Toxicology 125: 1-11 (1998).
100. Bojes, H.K., Suresh, P.K., Mills, E.M., Spitz, D.R. and Kehrer, J.P.: Bcl-2 and bcl-xL in peroxide resistant A549 and U87MG cells. Toxicolog. Sci 42: 109-116 (1998).
101. Datta, K., Biswal, S.S., Xu, J., Towndrow, K.M., Feng, X. and Kehrer, J.P.: A relationship between 5-lipoxygenase activating protein (FLAP) and bcl-x expression in murine pro B- lymphocytic FL5.12 cells. J. Biol. Chem. 273: 28163-28169 (1998).
102. Bojes, H.K., Feng, X., Kehrer, J.P. and Cohen, G.M.: Apoptosis in hematopoietic cells (FL5.12) caused by interleukin-3 withdrawal: relationship to caspase activity and the loss of
glutathione. Cell Death Different. 6: 61-70 (1999).
103. Kehrer, J.P.: Systemic pulmonary toxicity, in General and Applied Toxicology, 2nd Edition (B. Ballantyne, T. Marrs, and Syversen, eds.), MacMillan Press, New York, pp. 721-736(volume 2) (1999).
104. Horton, N.D., Biswal, S.S., Corrigan, L.L., Bratta, J. and Kehrer, J.P.: Acrolein causes IκB- independent decreases in NF-κB activation in human lung adenocarcinoma (A549) cells through the formation of p50 adducts. J. Biol. Chem. 274: 9200-9206 (1999).
105. Datta, K., Biswal, S.S. and Kehrer, J.P.: The 5-lipoxygenase activating protein (FLAP) inhibitor, MK886, induces apoptosis independent of FLAP. Biochem. J. 340: 371-375
(1999).
106. Robertson, J.D., Datta, K., Biswal, S.S. and Kehrer, J.P.: Hsp70 antisense oligomers enhance proteasome inhibitor-induced apoptosis. Biochem. J. 344: 477-485 (1999).
107. Biswal, S.S., Datta, K., Shaw, S.D., Feng, X., Robertson, J.D. and Kehrer, J.P.: Glutathione oxidation and mitochondrial depolarization as mechanisms of nordihydroguaiaretic acid-induced
apoptosis in lipoxygenase-deficient FL5.12 cells. Toxicolog. Sci. 53: 77-83 (2000).
108. Kehrer, J.P.: Reductive stress, in Encyclopedia of Stress, (G. Fink, ed.) 3: 327-333 Academic
109. Kehrer, J.P. and Biswal, S.S.: The molecular effects of acrolein. Toxicolog. Sci. 57: 6-15
110. Kehrer, J.P.: Cause-effect of oxidative stress and apoptosis. Teratology 62: 235-236 (2000).
111. Kehrer, J.P.: The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 149: 43-50
112. Biswal, S.S., Datta, K., Acquaah-Mensah, G.K. and Kehrer, J.P.: Changes in ceramide, sphingomyelin and p53 following fludarabine treatment of human chronic B-cell leukemia
cells. Toxicology 154: 45-53 (2000).
113. Kehrer, J.P. and Mirsalis, J.: Professional toxicology societies: web-based resources.
Toxicology 157: 67-76 (2001).
Curriculum Vitae
Kehrer, J.P.
Page 19

114. Biswal, S.S., Datta, K. and Kehrer, J.P.: Association between bcl-x and 5-lipoxygenase activating protein (FLAP) levels in IL-3-dependent FL5.12 cells. Toxicology 160: 97-103
(2001).
115. Kehrer, J.P., Biswal, S.S., La, E., Thuillier, P., Datta, K., Fischer, S.M. and and Vanden Heuvel, J.P.: Inhibition of peroxisome proliferator activated receptor alpha (PPARα) by MK886. Biochem. J. 356: 899-906 (2001). For the 12 months ending November 2002 this
was the most downloaded regular research paper from the Biochem. J. 5079 downloads.
116. Datta, K., Kern, J.C., Biswal, S.S. and Kehrer, J.P.: Proteolysis and the loss of bcl-x in FL5.12 cells undergoing apoptosis induced by MK886. Toxicol. Appl. Pharmacol.174: 273-
281 (2001).
117. Acquaah-Mensah, G.K., Leslie, S.W. and Kehrer, J.P.: Acute exposure of cerebellar granule neurons to ethanol suppresses stress-activated protein kinase-1 and concomitantly induces
AP-1. Toxicol. Appl. Pharmacol.175: 10-18 (2001).
118. Biswal, S., Acquaah-Mensah, G., Datta, K., Wu, X. and Kehrer, J.P.: Inhibition of cell proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to
thiol imbalance and covalent modifications. Chem. Res. Toxicol. 15:180-186 (2002).
119. Tang, D.G., La, E., Kern, J. and Kehrer, J.P.: Fatty acid oxidation and signaling in apoptosis.
Biological Chem. 383, 425-442 (2002).
120. Kern, J.C. and Kehrer, J.P.: Acrolein-induced cell death: a caspase-influenced decision between apoptosis and oncosis/necrosis. Chemico-Biol. Interact. 139, 79-95 (2002).
121. Acquaah-Mensah, G.K., Kehrer, J.P. and Leslie, S.W.: Altered cerebellar transcriptional regulation in a rat fetal alcohol syndrome model. J. Pharmacol. Exptl. Therap. 301: 277-283(2002).
122. Thuillier, P., Brash, A.R., Kehrer, J.P., Stimmel, J.B., Leesnitzer, L.M., Yang, P., Newman, R.A. and Fischer, S.M.: Inhibition of PPAR-mediated keratinocyte differentiation by
lipoxygenase inhibitors. Biochem. J. 366, 901-910 (2002).
123. La, E., Kern, J.C., Atarod, E.B. and Kehrer, J.P.: Fatty acid release and oxidation in lipoxygenase inhibitor-induced apoptosis. Toxicol. Lett. 138, 193-203 (2003).
124. Biswal, S., Maxwell, T., Rangasamy, T. and Kehrer, J.P.: Modulation of benzo[a]pyrene- induced p53 DNA activity by acrolein. Carcinogenesis 24, 1401-1406 (2003).
125. Tong, Z., Wu, X. and Kehrer, J.P.: Increased expression of the lipocalin 24p3 as an apoptotic mechanism for MK886. Biochem. J. 372, 203-210 (2003).
126. Wu, X. Biswal, S.S. and Kehrer, J.P.: Roles of 5-lipoxygenase activating protein in cell proliferation and apoptosis. Cell Biol. Toxicol. 19, 135-143 (2003).
127. Watson, W.H., Yang, X., Choi, Y.E., Jones, D.P. and Kehrer, J.P.: Thioredoxin and its role in toxicology. Toxicolog. Sci. 78, 3-14 (2004).
128. Atarod, E. B. and Kehrer, J.P.: Dissociation of oxidant production by peroxisome proliferator activated receptor ligands from cell death in human cell lines. Free Rad. Biol. Med. 37, 36-47
(2004).
Curriculum Vitae
Kehrer, J.P.
Page 20

129. Kern, J.C. and Kehrer, J.P.: Free radicals and apoptosis: relationships with glutathione, thioredoxin and the bcl family of proteins. Frontiers in Bioscience 10, 000-000 (2005).
130. Yang, X., Wu, X., Choi, Y.E., Kern, J.C. and Kehrer, J.P.: Effect of acrolein and glutathione depleting agents on thioredoxin. Toxicology 204, 209-218 (2004).
131. Tong, Z., Wu, X., Ovcharenko, D., Zhu, J., Chen, C-S. and Kehrer, J.P.: Neutrophil gelatinase associated lipocalin as a survival factor. (submitted).
132. Tong, Z., Wu, X., and Kehrer, J.P.: Inhibition of Akt by lipoxygenase inhibitors that induce 133. Tang, D.G. and Kehrer, J.P.: Carcinogenesis – Balance between apoptosis and survival pathways. In "Apoptosis, Cell Signaling, and Human Disease: Molecular Mechanisms, TheHuman Press, Inc., R. Srivastava, editor. (in press, 2005).
134. Kehrer, J.P.: Reductive stress, in Encyclopedia of Stress, (G. Fink, ed., 2nd edition) Elsevier, Curriculum Vitae
Kehrer, J.P.
Page 21

ABSTRACTS
Kehrer, J.P. and Autor, A.P.: Age-dependent lipid peroxidation in neonatal rat lungs. Fed.
Proc.
35: 1402, #234 (1976).
Kehrer, J.P. and Autor, A.P.: Alterations in the fatty acid composition of lung phospholipids
and triglycerides following age-dependent lipid peroxidation in neonatal rat lungs. Toxicol.
Appl. Pharmacol.
41: 184, 1977.
Kehrer, J.P. and Autor, A.P.: Triglycerides as a specific substrate for age-dependent lipid
peroxidation in neonatal rat lungs. Fed. Proc. 36: 983,#3761, 1977.
Kehrer, J.P. and Autor, A.P.: Fatty acid desaturase activity and the incorporation of poly-
unsaturated fatty acids into lipids of the postnatally developing rat lung. Fed. Proc. 37: 719,
#2654, 1978.
5. Kehrer, J.P., Haschek, W. and Witschi, H.P.: Peracute toxicity of paraquat and diquat in 100% oxygen. Toxicol. Appl. Pharmacol. 48: A59, 1979.
6. Kehrer, J.P. and Witschi, H.P.: The role of metabolism in the pulmonary toxicity of butylated hydroxytoluene. Fed. Proc. 38: 582, #1872, 1979.
7. Kehrer, J.P. and Witschi, H.P.: In vivo collagen synthesis in an experimental model of pulmonary fibrosis. Fed. Proc. 39: 364, #492, 1980.
8. Kehrer, J.P. and Witschi, H.P.: The effect of indomethacin and prednisolone on pulmonary fibrosis produced by treatment with butylated hydroxytoluene and oxygen. The Toxicologist
1: 56, #203, 1981.
9. Kehrer, J.P. In vitro rates of collagen synthesis in mouse lung tissue following the administration of butylated hydroxytoluene. The Toxicologist 2: 187, #653, 1982.
10. Kehrer, J.P.: The direct effect of prednisolone on collagen synthesis in acutely damaged lung tissue. Texas Pharmacologists (1982).
11. Kehrer, J.P.: Enhanced acute lung damage following the administration of corticosteroids.
The Toxicologist 3: 109 #435 (1983).
12. Kehrer, J.P.: The inhibition of tissue glutathione reductase activity by BCNU. Assoc. Mex.
13. Kehrer, J.P.: The effect of BCNU-treatment on damaged lung tissue. The Toxicologist 4: 57,
14. Paraidathathu, T., Combs, A.B., and Kehrer, J.P.: BCNU-enhanced doxorubicin toxicity. The Toxicologist 4: 169, #674 (1984).
15. Kehrer, J.P. and Murphy, M.A.: Effect of BCNU on acetaminophen-induced hepatotoxicity.
Fed. Proc. 43: 935, #3802 (1984).
16. Murphy, M.E. and Kehrer, J.P.: Antioxidant enzyme activities and fluorescent compounds in normal and dystrophic chicken muscle. Texas Pharmacologists, 1985 17. Smith, R.D. and Kehrer, J.P.: The hepatotoxic effects of a combination of acetaminophen and 1,3-bis(2-chloroethyl)-1-nitrosourea in mice. Texas Pharmacologists, 1985.
Curriculum Vitae
Kehrer, J.P.
Page 22

18. Kehrer, J.P.: Collagen metabolism in normal and damaged mouse lung tissue following treatment with prednisolone. The Toxicologist 5: 34, #136 (1985).
19. Lee, Y-C.C. and Kehrer, J.P.: In vivo versus in vitro rates of pulmonary collagen synthesis.
Fed. Proc. 44: 1063, #3813 (1985).
20. Smith, R.D. and Kehrer, J.P.: The hepatotoxic effects of a combination of BCNU and acetaminophen in mice. The Toxicologist 6: 154, #621 (1986).
21. Murphy, M.E. and Kehrer, J.P.: Age-dependent changes in antioxidant enzyme activities in four tissues of normal and muscular dystrophic chickens.The Toxicologist 6: 151, #610 (1986).
22. Kehrer, J.P. and Klein-Szanto, A.J.P.: Lung damage in mice treated with O,S,S-trimethyl phosphorodithioate. Fed. Proc. 45: 743 #3415 (1986).
23. Kehrer, J.P.: Lung damage and collagen synthesis after intratracheal anticancer drugs or parenteral cyclophosphamide. Europ. Soc. Toxicol. (1986).
24. Kehrer, J.P. and Murphy, M.E.: Elevated antioxidant enzyme activities in four tissues of normal and dystrophic chickens: Evidence for oxidative stress? Soc. Free Rad. Res. (1986).
25. Kehrer, J.P. and Sies, H.: Absence of changes in xanthine oxidase activity following hypoxia and reoxygenation in isolated perfused rat heart tissue. Soc. Free Rad. Res. (1986).
26. Kehrer, J.P. and Sies, H.: Inhibition of enzyme release from isolated perfused rat heart upon reoxygenation by cyanide and cystamine. The Toxicologist 7: 93, #372 (1987).
27. Wright, E.S., Kehrer, J.P., White, D.M. and Smiler, K.L.: Effects of chronic exposure to ozone on collagen metabolism in rat lung. The Toxicologist 7: 186, #744 (1987).
28. Park, Y.J., Smith, R.D., Combs, A.B. and Kehrer, J.P.: Effects of BCNU on acetaminophen biotransformation and glutathione-S-transferase. The Toxicologist 7: 116, #465 (1987).
29. Murphy, M.E. and Kehrer, J.P.: Tocopherols and enzymatic membrane antioxidants in avian muscular dystrophy. Fed. Proc. 46: 1151, #4867 (1987).
30. Kehrer, J.P. and Murphy, M.E.: Tocopherol metabolism in liver and muscle tissue from normal and dystrophic chickens. "Role of Oxygen Radicals and Antioxidants in Cancer andAging", Satellite meeting of the Society for Free Radical Research, Feb. 1987.
31. Park, Y., Smith, R.D., Combs, A.B. and Kehrer, J.P.: Effects of BCNU on acetaminophen toxicity and glutathione-S-transferase. Texas Pharmacologists, May 1987.
32. Murphy, M.E. and Kehrer, J.P.: Analysis of tocopherols and tocopheryl quinones by HPLC with redox cycling electrochemical detection. The Pharmacologist 29: 209, #551 (1987).
33. Murphy, M.E. and Kehrer, J.P.: Increased oxidation of tocopherols in chickens with inherited muscular dystrophy. Fourth International Congress on Oxygen Radicals (Invited abstract, pp.
48-51, 1987).
34. Park, Y. and Kehrer, J.P.: Energy-dependent enzyme release from hypoxic heart tissue perfused with calcium-free medium. The Toxicologist 8: 190, #755 (1988).
Curriculum Vitae
Kehrer, J.P.
Page 23

35. Smith, R.D. and Kehrer, J.P.: Pretreatment with cyclophosphamide does not protect against the lung damage and fibrosis of a second dose. The Toxicologist 8: 3, #11 (1988).
36. Kehrer, J.P. and Murphy, M.E.: Tocopheryl quinones in genetic muscular dystrophy in chickens. Soc. Free Rad. Res. (1988).
37. Kehrer, J.P.: Increased bleomycin toxicity in mice with butylated hydroxytoluene-induced lung damage. FASEB J. 2: A1559, #7338 (1988).
38. Kehrer, J.P. and Murphy, M.E.: Factors inhibiting lipid peroxidation in liver and muscle of rat, mouse and chicken. The Toxicologist 9: 156, #624 (1989).
39. Park, Y. and Kehrer, J.P.: Oxidative changes in hypoxic-reoxygenated rat myocardium. The Toxicologist 9: 277, #1111 (1989).
40. Smith, R.D. and Kehrer, J.P.: Lung injury and fibrosis in mice given one or two doses of cyclophosphamide. The Pharmacologist 31: 176, #310 (1989).
41. Kehrer, J.P. and Park, Y.: Oxidative stress during hypoxia in isolated-perfused rat heart. 4th International Symposium on Biological Reactive Intermediates. (1990) 42. Palamanda, J. and Kehrer, J.P.: Inhibition of lipid and protein oxidation in rat liver microsomes by glutathione. The Toxicologist 10: 24, #96 (1990).
43. Fraiser, L. and Kehrer, J.P.: Metabolism of bleomycin by normal and damaged mouse lung tissue. The Toxicologist 10: 99, #395 (1990).
44. Kehrer, J.P. and Park, Y.: Protection by ruthenium red against hypoxia-reoxygenation injury in rat myocardium. The Toxicologist 10: 34, #136 (1990).
45. Bowles, D.K., Torgan, C.E., Ebner, S., Kehrer, J.P., Ivy, J.L. and Starnes, J.W.: Effects of acute, submaximal exercise on skeletal muscle vitamin E. Med. Sci. Sports Ex. 22: S74 (1990).
46. Kehrer, J.P. and Smith, R.D.: Cyclophosphamide cooxidation by prostaglandin H synthase: an alternative bioactivation mechanism. Proc. West. Pharmacol. Soc. 34: 524 (1991).
47. Palamanda, J. and Kehrer, J.P.: Inhibition of iron-ascorbate stimulated lipid peroxidation in rat liver microsomes by purine and pyrimidine triphosphates.The Toxicologist 11: 215 #799
(1991).
48. Kanekal, S. and Kehrer, J.P.: Arachidonic acid-dependent metabolic activation of cyclophosphamide. The Toxicologist 11: 258 #978 (1991).
49. Paraidathathu, T., de Groot, H. and Kehrer, J.P.: Production of reactive oxygen species (ROS) by rat heart mitochondria: effect of calcium and ischemia. The Toxicologist 11: 98 #308
(1991).
50. Fraiser, L. and Kehrer, J.P.: Evidence for a role of prostaglandin H synthase (PHS) in cyclophosphamide toxicity in mice. The Toxicologist 11: 257 #977 (1991).
51. Seiler, K.S., Kehrer, J.P. and Starnes, J.W.: Increased perfusion pressure improves recovery in hypoxic rat heart. FASEB J. 5: A1045 #3919 (1991).
52. Kanekal, S. and Kehrer, J.P.: Strain differences in cyclophosphamide-induced pulmonary fibrosis. FASEB J. 5: A1569 #6957 (1991).
Curriculum Vitae
Kehrer, J.P.
Page 24

53. Spitz, D.R., Kinter, M.T., Kehrer, J.P., Adams, D.T., Sherman, C.M. and Roberts, R.J.: The effect of unsaturated fatty acids linoleic or eicospentaenoic acid, on O2-toxicity in cultured cells. Pediatr. Res. 29: 331A #1967 (1991).
54. Palamanda, J. and Kehrer, J.P.: Inhibition of microsomal lipid peroxidation by glutathione and nucleoside triphosphates. The Toxicologist 12: 175 #622 (1992).
55. Fraiser, L. and Kehrer, J.P.: Metabolism and bladder toxicity of cyclophosphamide in mice.
The Toxicologist 12: 289 #1115 (1992).
56. Paraidathathu, T. and Kehrer, J.P.: Production of reactive oxygen species by cardiac mitochondria and in isolated-perfused rat heart tissue. The Toxicologist 12: 74 #196 (1992).
57. Kanekal, S., Fraiser, L., Davis, J. and Kehrer, J.P.: Metabolism of cyclophosphamide (CP) by peroxidases. The Toxicologist 12: 330 #1279 (1992).
58. Seiler, K.S., Kehrer, J.P. and Starnes, J.W.: Exogenous glutathione (GSH) prevents myocardial stunning following intermittent hypoxia in isolated rat hearts. FASEB J. 6: A1341
#2347 (1992).
59. Paraidathathu, T., Lund, L.G. and Kehrer, J.P.: Changes in high energy phosphates, glutathione, and pyridine nucleotides in hypoxic heart tissue exposed to diamide. The
Toxicologist
13: 119 #382 (1993).
60. Fraiser, L., Skarovsky, C. and Kehrer, J.P.: Bioactivation of a glutathione-acrolein conjugate to bladder toxic species. The Toxicologist 13: 226 #836 (1993).
61. Kehrer, J.P. and Kanekal, S.: Arachidonic acid (AA)-mediated metabolism and cytotoxicity of cyclophosphamide (CP) in NCI H358 pneumocytes. The Toxicologist 13: 384 #1504 (1993).
62. Kanekal, S. and Kehrer, J.P.: Metabolism of cyclophosphamide (CP) by soybean lipoxygenases. The Toxicologist 13: 385 #1505 (1993).
63. Kehrer, J.P.: Effects of oxygen deprivation in cardiac injury. Proc. West. Pharmacol. Soc. 64. Kanekal, S. and Kehrer, J.P.: Prostaglandin H synthase (PHS) inhibitors decrease the antineoplastic effect of cyclophosphamide (CP) in vivo. FASEB J. 7: A690, #3988 (1993).
65. Kehrer, J.P. and Lund, L.G.: Pyridine nucleotides and the reduction of GSSG in hypoxic heart tissue exposed to diamide. Free Rad. Biol. Med. 15: 520, #7:19 (1993).
66. Lund, L.G., Paraidathathu, T. and Kehrer, J.P.: Reduction of glutathione disulfide (GSSG) and the maintenance of reducing equivalents in hypoxic rat hearts after infusion with diamide. The
Toxicologist
14: 170, #611 (1994).
67. Perry, C.S., Liu, X.L., Lund, L.G. and Kehrer, J.P.: The effect of cyclophosphamide (CP) and its metabolites on the growth of cultured A549 cells. The Toxicologist 14: 113, #370 (1994).
68. Mulumudi, M. and Kehrer, J.P.: Possible roles for 3-oxopropyl (3-oxoPrMCA) and 3- hydroxypropyl (3-hydroxyPrMCA) mercapturic acids in cyclophosphamide (CP)-induced
bladder damage. The Toxicologist 14: 113, #369 (1994).
Curriculum Vitae
Kehrer, J.P.
Page 25

69. Stevenson, D.E., Kehrer, J.P., Kolaja, K.L., Walborg, E.F. and Klaunig, J.E.: Effects of dietary antioxidants on dieldrin-induced hepatic effects in B6C3F1 mice. 7th International Conference 70. Lund, L.G., Liu, H. and Kehrer, J.P.: Glutathione disulfide (GSSG) reduction after t-butyl hydroperoxide (tBOOH)-induced oxidative stress in isolated hepatic mitochondria. FASEB J.
8: A672, #3899 (1994).
71. Liu, H.L. and Kehrer, J.P.: Reduction of glutathione disulfide in oxidatively stressed respiring rat liver mitochondria. The Toxicologist 15: 280 #1500 (1995).
72. Kehrer, J.P., Ramu, K., and Mamiya, B.: Synthesis and characterization of the mercapturic acids of acrolein. The Toxicologist 15: 267 #1430 (1995).
73. Ramu, K., Ahmed, T., Fraiser, L. and Kehrer, J.P.: Acrolein mercapturates and the bladder toxicity of cyclophosphamide. The Toxicologist 15: 304 #1628 (1995).
74. Perry, C.S. and Kehrer, J.P.: Effects of glutathione-acrolein conjugates on the thiol status of A549 cells. The Toxicologist 15: 304 #1627 (1995).
75. Liu, X-L., Perry, C.S., Lund, L.G. and Kehrer, J.P.: Effect of cyclophosphamide and its metabolites on growth of cultured A549 cell and protective effects of glutathione and N-
acetylcysteine. Acta Pharmacologica Sinica 16: 75 (1995).
76. Kehrer, J.P., Awasthi, S., Spitz, D.R. and Smith, C.V.: Peroxide toxicity and bcl-2 in human tumor cell lines. Free Rad. Biol. Med. abstract book (1995).
77. Ramu, K., Perry, C.S., Ahmed, T., Pakenham, G. and Kehrer, J.P.: Mechanisms of acrolein mercapturate toxicity. Fundam. Appl. Toxicol. 30: 284 #1455 (1996).
78. Kehrer, J.P., Suresh, P.K. and Spitz, D.R.: Peroxide resistance and bcl-2 expression in human tumor cell lines. Fundam. Appl. Toxicol. 30: 242 #1241 (1996).
79. Suresh, P.K., Awasthi, S., Smith, C.V. and Kehrer, J.P.: Peroxide toxicity and bcl-2 in A549 cells. Fundam. Appl. Toxicol. 30: 245, #1254 (1996).
80. Swift, J.N., Seiler, K.S., Kehrer, J.P. and Starnes, J.W.: Depletion and resynthesis of antioxidants following exercise. Med. Sci. Sports Exerc. 28: #177 (1996).
81. Bojes, H.K., Mills, E.M. and Kehrer, J.P.: BCL-xL expression and α−tocopherol in human lung adenocarcinoma A549 cells. The Oxygen Society (1996).
82. Datta, K., Chin, A., Ahmed, T., Qing, W-G., Powell, K.L., Simhambhatla, P., MacLeod, M.C.
and Kehrer, J.P.: Protection against cyclophosphamide-mediated lung and bladder toxicity in
mice by 2,6-dithiopurine. Fundam. Appl. Toxicol. 36: 213, #1080 (1997).
83. Robertson, J.D., Starnes, J.W. and Kehrer, J.P.: Reducing cosubstrates involved in reducing cardiac glutathione disulfide. Fundam. Appl. Toxicol. 36: 299, #1520 (1997).
84. Horton, N.D., Mamiya, B.M., Bojes, H.K. and Kehrer, J.P.: Relationships between glutathione levels, cell density and proliferation of A549 cells following treatment with acrolein. Fundam.
Appl. Toxicol.
36: 126, #642 (1997).
Curriculum Vitae
Kehrer, J.P.
Page 26

85. Datta, K., Xu, J.and Kehrer, J.P.: Changes in bcl-xL and 5-lipoxygenase activator protein (FLAP) expression following induction of apotposis by a FLAP inhibitor in FL5.12 cells. The
Toxicologist
42: 190, #938 (1998).
86. Bojes, H.K., Cohen, G.M. and Kehrer, J.P.: Depletion of intracellular glutathione (GSH) causes apoptosis in FL5.12 cells. The Toxicologist. 42: 356, #1756 (1998).
87. Horton, N.D., Corrigan, L. and Kehrer, J.P.: The possible role of glutathione (GSH) in acrolein-decreased NF-κB activation and cell proliferation. The Toxicologist. 42: 278, #1368
88. Robertson, J.D., Datta, K., Xu, J. and Kehrer, J.P.: Bcl-xL overexpression restricts hsp70i production and heat-induced apoptosis in FL5.12 cells. The Toxicologist. 42: 145, #716
(1998).
89. Robertson, J.D. and Kehrer, J.P.: Proteasome inhibition induces hsp70 and promotes apoptosis which is abated by bcl-x overexpression in murine pro-B lymphocytic (FL5.12) cell lines. Presented at 'Mechanisms of Toxicity Gordon Research Conference, Summer 1998 90. Biswal, S., Datta, K. and Kehrer, J.P.: N-Acetyl cysteine (NAC) partially blocks fludarabine- induced apoptosis in CLL cell lines by acting downstream of caspase-3 activation. The
Toxicologist.
48: 155, #727 (1999).
91. Datta, K. and Kehrer, J.P.: MK886, a 5-lipoxygenase activating protein (FLAP) inhibitor, induces FLAP-independent apoptosis in FL5.12 cells. The Toxicologist. 48: 154, #725 (1999).
92. Robertson, J.D., Datta, K. and Kehrer, J.P.: Proteasome inhibition induces HSP70 and promotes apoptosis which is decreased by bcl-x overexpression in murine pro-B lymphocytic (FL5.12) cells. The Toxicologist. 48: 157, #735 (1999).
93. Acquaah-Mensah, G., Biswal, S.S., Kehrer, J.P. and Leslie, S.W.: Redox-sensitive transcription activity is suppressed at second day post-natal (PD2) in Sprague Dawley rat fetal
alcohol syndrome model. Alcoholism, Clin. Exptl. Res. 23: 62A #342 (1999).
94. Biswal, S., Acquaah-Mensah, G., Pabalan, J., Datta, K. and Kehrer, J.P.: Effect of acrolein on AP-1 and gene expression in A549 cells. The Toxicologist 54: 391, #1836 (2000).
95. Kehrer, J.P., Biswal, S., Thuillier, P., Vanden Heuvel, J.P. and Fischer, S.: Inhibition of peroxisome proliferator activated receptor alpha by MK886. The Toxicologist 54: 323, #1513
(2000).
96. Datta, K., Biswal, S. and Kehrer, J.P.: Role of proteolysis in bcl-x depletion during MK886- induced apoptosis in FL5.12 cells. The Toxicologist 54: 358, #1678 (2000).
97. Kern, J.C. and Kehrer, J.P.: Acrolein enhances mechlorethamine-induced apoptosis. The Toxicologist. 54: 113, #534 (2000).
Kehrer, J.P.: The Haber-Weiss reaction and mechanisms of toxicity. The Toxicologist. 54:
129, #611 (2000).
Biswal, S., Thuillier, P., Vanden Heuvel, J.P., Fischer, S. and Kehrer, J.P.: 5-lipoxygenase
activating protein inhibitor , MK886, inhibits peroxisome proliferator activated receptor alpha
in different cell lines. Proc. Am. Assoc. Cancer Res. 91: 374, #2373 (2000).
Curriculum Vitae
Kehrer, J.P.
Page 27

100. Pabalan, J.G., Biswal, S.S., Bowman, P. and Kehrer, J P.: Investigation of anticancer activity of all-trans-(4-hydroxyphenyl) retinamide in human lung adenocarcinoma A549 cells. Proc.
Am. Assoc. Cancer Res.
91: 618, #3929 (2000).
101. Dubick, M.A., Pabalan, J.G., Biswal, S., Jordan, B.S., Kehrer, J.P., Goodwin, C.W. and Bowman, P.D.: Gene expression profiling of the response of human small airway epithelial
cells (SAEC) to Douglas Fir smoke. FASEB J. 14: 134.4 (2000).
102. Pabalan, J.G., Kehrer, J.P., Goodwin, C.W. and Bowman, P.D.: Gene expression profiling of the response of human keratinocytes to all trans retinoic acid (ATRA). FASEB J. 14:
270.12 (2000).
103. Acquaah-Mensah, G.K., Kehrer, J.P. and Leslie, S.W.: Evidence of ethanol-induced molecular stress during neurodevelopment. Alcoholism, Clin. Exptl. Res. 24: 31A #146
(2000).
104. Deshpande, V. and Kehrer, J.P.: N-Acetylcysteine enhances apoptosis induced by the 5- lipoxygenase activating protein (FLAP) inhibitor MK886 in Jurkat cells. The Toxicologist.
60: #1334 (2001).
105. Biswal, S.S., Bowman, P., Datta, K. and Kehrer, J.P.: Smoke- and acrolein-mediated effects on AP-1 activation and gene expression. The Toxicologist. 60: #1024 (2001).
106. Datta, K., Kern, J.C., Biswal, S.S. and Kehrer, J.P.: Proteolytic depletion of bcl-x and induction of lysosomal degranulation during MK886-induced apoptosis in FL5.12 cells.
The Toxicologist. 60: #1336 (2001).
107. Kern, J.C., Chung, B.C. and Kehrer, J.P.: The importance of caspases in acrolein-induced oncosis. The Toxicologist. 60: #1337 (2001).
108. Acquaah-Mensah, G.K., Kehrer, J.P. and Leslie, S.W.: Activation of glycogen synthase kinase-3 in a fetal alcohol syndrome model. Alcoholism, Clin. Exptl. Res. 25: 75A (2001).
109. Kehrer, J.P. and La, E.: Role of fatty acid release and oxidation in apoptosis induced by lipoxygenase (LOX) inhibitors. Free Rad. Biol. Med. 31: 314 Suppl. 1 (2001).
110. Kern, J.C. and Kehrer, J.P.: Acrolein depletes glutathione and thioredoxin in human bronchiolar cancer cells. The Toxicologist 66: #702, 144 (2002).
111. Kehrer, J.P.: Introduction to thioredoxins and thioredoxin reductases: central roles in toxicity and cancer. The Toxicologist 66: #270, 56 (2002).
112. La, E, and Kehrer, J.P. Fatty acid release and oxidation as factors in the apoptosis induced by lipoxygenase inhibitors. The Toxicologist 66: #1102, 225 (2002).
113. Biswal, S.S., Maxwell, T. and Kehrer, J.P.: Modulation of benzo(a)pyrene-induced p53 by acrolein. The Toxicologist 66: #1504, 307 (2002).
114. Deshpande, V.S. and Kehrer, J.P.: Mechanisms by which N-acetylcysteine enhances MK886-induced apoptosis. Proc. Am. Assoc. Cancer Res. 43: 533, #2645 (2002).
115. Thuillier P., Brash, A.R., Kehrer, J.P., Stimmel, J.B., Leesnitzer, L.M., Yang, P.Y,. Newman, R.A. and Fischer, S.M.: Inhibitory effects of lipoxygenase inhibitors on PPAR mediated
keratinocyte differentiation. Cancer Epidemiol. Biomark. Prevent. 11: C318 Part 2 (2002).
Curriculum Vitae
Kehrer, J.P.
Page 28

116. Atarod, E.B. and Kehrer, J.P.: Oxidant production and apoptosis in response to PPAR agonists and antagonists. Free Rad. Biol. Med. 33: S403 #306 Suppl. 1 (2002).
117. Kern, J.C. and Kehrer, J.P.: The importance of thioredoxin in acrolein-mediated alterations of NF-κB and AP-1 DNA binding in A549 cells. Free Rad. Biol. Med. 33: 353 #146
118. Tong, Z., Wu, Z. and Kehrer, J.P.: Modulation of lipocalin 24p3 expression as an apoptotic mechanism for MK886. The Toxicologist (2003).
119. Atarod, E.B. and Kehrer, J.P.: Changes in cellular oxidant production in response to peroxisome proliferators activated receptor (PPAR) α and γ agonists and the PPAR antagonist MK886. The Toxicologist (2003).
120. Deshpande, V.S. and Kehrer, J.P.: Leucine affects protein translation and apoptosis mediated by MK886 in Jurkat cells. Proc. Am. Assoc. Cancer Res. 44: 1397 #6091 (2003).
121. Tong, Z., Wu, X. and Kehrer, J.P.: The association of apoptosis with the induction of neutrophil gelatinase associated lipocalin (NGAL). The Toxicologist 78: #1629 (2004).
122. Choi, Y.E., Yang, X. and Kehrer, J.P.: Thioredoxin and the toxicity of acrolein. The Toxicologist 78: #972 (2004).
123. Deshpande, V.S. and Kehrer, J.P.: Mechanisms of nordihydroguaiaretic acid (NDGA)- mediated apoptosis in FL5.12 cells. The Toxicologist 78: #1633 (2004).
124. Tong, Z., Wu, X. and Kehrer, J.P.: Akt plays a role in the apoptosis induced by the 5- lipoxygenase activating protein (FLAP) inhibitor, MK886. The Toxicologist 78: #1630
(2004).
125. Tipple, T.E., Choi, Y.E., Rogers, L.K., Hansen, T.N., Welty, S.E., Kehrer, J.P., and Smith, C.V.: Enhanced expression of thioredoxin-2 in mice genetically deficient in glutathionereductase. Pediatr Res. 2004.
126. Choi, Y.E. and Kehrer, J.P.: IAP expression is deceased in cells undergoing apoptosis after treatment with phosphoinositide-dependent kinase 1 (PDK1) inhibitors. Exp. Biol. (2005) 127. Kehrer, J.P., Wu, X., Zhu, J., Chen, C-S., and Tong, Z.: Induction of apoptosis by phosphoinositide-dependent kinase 1 (PDK1) inhibitors in human non-small cell lungcancer A549 cells is through the mitochondrial pathway. Exp. Biol. (2005) 128. Mitra, S. and Kehrer, J.P.: Mechanisms of diethylmaleate (DEM)-mediated apoptosis in human T lymphocyte Jurkat cells. Exp. Biol. (2005) 129. Tong, Z., Wu, X., Ovcharenko, D. and Kehrer, J.P.: Neutrophil gelatinase associated lipocalin (NGAL) and 24p3 as survival factors. Exp. Biol. (2005) 130. Deshpande, V.S. and Kehrer, J.P.: Nordihydroguairetic acid (NDGA)-induced apoptosis involves activation of the extracellular signal-regulated kinase (ERK) and c-jun-NH2 terminal kinase (JNK) pathways. Exp. Biol. (2005) Curriculum Vitae
Kehrer, J.P.
Page 29

Book Reviews
1. The Role of Chemical Mediators in the Pathophysiology of Acute Illness and Injury. R.
McConn (ed.). Raven Press, NY, 1982. Amer. J. Pharmac. Ed. 47: 195 (1983).
Cancer of the Respiratory Tract: Predisposing Factors. (Carcinogenesis - A Comprehensive
Survey, Vol. 8) M.J. Mass, D.G. Kaufman, J.M. Siegfried, V.E. Steele and S. Nesnow (eds.)
Raven Press, NY, 1985. J. Toxicol. Environ. Health 16: 661-662 (1985).
New Concepts and Developments in Toxicology. (Proceedings of the Fourth International
Congress of Toxicology held in Tokyo, Japan, July 21-25, 1986.) P.L. Chambers, P. Gehring
and F. Sakai, (eds.) Elsevier, Amsterdam, 1986. J. Toxicol. Environ. Health 22: 363-364
(1987).
A Textbook of Modern Toxicology. E. Hodgson and P.E. Levi, Elsevier, NY, 1987. J. Toxicol.
Environ. Health 23: 140-141 (1988).
Lipid Peroxidation in Biomembranes. V.E. Kagan, CRC, Boca Raton, FL, 1988. Free Rad.
Biol. Med. 6: 447 (1989).
Combination Effects in Chemical Carcinogenesis. D. Schmähl, VCH, Weinheim, FRG, 1988.
J. Toxicol. Environ. Health 26: 510-511 (1989).
Concepts in Inhalation Toxicology. R. McClellan and R. Henderson (eds.) Hemisphere,
London, 1989. Toxicol. Lett. 48: 213-214 (1989).
Introduction to Toxicology. by J.A. Timbrell, Taylor & Francis, London, 1989. Toxicol. Lett.
51: 233-234 (1990).
Basic Toxicology: Fundamentals, Target Organs, and Risk Assessment. by Frank C. Lu,
Hemisphere, Philadelphia, 1991. Toxicol. Lett. 55: 351-352 (1991).
10. Hazardous Materials Toxicology: Clinical Priciples of Environmental Health. J.B. Sullivan and G.R. Krieger (eds.), Williams & Wilkins, 1992. Toxicol. Lett. 61: 319-320 (1992).
11. Toxicology of the Lung. D.E. Gardner, J.D. Crapo, and R.O. McClellan (eds.), Raven, 1992.
Toxicol. Lett. 70: 123-124 (1994).
Professional Publications
1. "Consumer Drug File": A drug information column for the general public.
Syndicated by: International Medical Tribune Syndicate Written by: Dr. James P. Kehrer and Daniel M. Kehrer from March 1982 - Feb. 19852.
Kehrer, J.P. and Kehrer, D.M.: The real dope on diet drugs. New Body 1, 22 (1982).
Kehrer, J.P. and Kehrer, D.M.: Consumers benefit from advertising prescription drugs.
Newsday, July 23, 1982. p. 68.
Kehrer, J.P. and Kehrer, D.M.: Pills have a success story to be told.but are they necessary incapsule form? The Philadelphia Inquirer, Oct. 13, 1982, p. 15A.
Kehrer, D.M. and Kehrer, J.P.: Pain Relievers and Packaging. St. Louis Post-Dispatch,October 24, 1982.
Kehrer, J.P. and Kehrer, D.M.: Tylenol Tampering Scare Raises Questions. AustinAmerican-Statesman, November 11, 1982, A24.
Kehrer, J.P. and Kehrer, D.M.: Going Underground for Birth Control. Des Moines Register,March 14, 1983, 7A.
Kehrer, D.M. and Kehrer, J.P.: Revolution Over the Counter. Amer. Health 2, 96 (1983).
Kehrer, J.P. and Kehrer, D.M.: Birth-control drug no-win proposition. Austin American-Statesman, May 25, 1983, A11.
10. Kehrer, J.P. and Kehrer, D.M.: New ways to take drugs. Fact 2, 23 (1983).
11. Kehrer, J.P. and Kehrer, D.M.: New consumer drug discoveries. Fact 2, 72 (1983).
12. Kehrer, D.M. and Kehrer, J.P.: When advice is poison. Amer. Health 3, 79 (1984).
13. Kehrer, D.M. and Kehrer, J.P.: What you must know about prescription drugs. Parade
14. Kehrer, D.M. and Kehrer, J.P.: Good-bye to pills and needles. Washington Post, April 9, Curriculum Vitae
Kehrer, J.P.
Page 30

15. Combs, A.B. and Kehrer, J.P.: How to convert a database from DB Master™ to MS File™.
Random Access 5 (4): 1 (1987).
16. Kehrer, J.P.: Introduction to Internet mail. Society of Toxicology Communiqué. January/ 16. Kehrer, J.P.: A brief introduction to internet mail. Eurotox Newsletter 18: 36-38 (1995).
"Pills and Potions: New Discoveries About Prescription and Over-the-Counter Drugs" by: James P.
Kehrer, Ph.D. and Daniel M. Kehrer. Publisher: Arco Press, New York, NY, April, 1984 This book was designed to acquaint the general public with recently approved drugs, other drugs which may beapproved in the near future, and coming changes in how drugs are delivered as part of our health care system.

Source: http://provost.wsu.edu/searches/Pharmacy/Kehrer.CV.pdf

Hypospadias in males with intrauterine growth restriction due to placental insufficiency: the placental role in the embryogenesis of male external genitalia

Hypospadias in Males With Intrauterine GrowthRestriction Due To Placental Insufficiency:The Placental Role in the Embryogenesis ofMale External GenitaliaYoav Yinon,1 John C.P. Kingdom,1 Leslie K. Proctor,1 Edmond N. Kelly,2 Joao L. Pippi Salle,3Diane Wherrett,4 Sarah Keating,5 Ori Nevo,6 and David Chitayat7*1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Placenta

What happened to my gut

What Happened To My Gut? (A Story About What CAN Happen To Your Bunny If You Don’t Feed It Right) By Sharon Hollars, DVM Nutrition is one of the main keys to keeping rabbits healthy. The first article, “I Know Bunnies Like Carrots, But What Should My Bunny REALLY Eat?” discusses what you SHOULD be feeding your bunny. This article covers some of the more common things that ca

Copyright © 2010-2014 Find Medical Article